New combo immunotherapy drug enters human trials for 18 cancers
NCT ID NCT05858736
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests a new drug called AI-061, which combines two immune-boosting antibodies (anti-PD-1 and anti-CTLA-4) into one treatment. The study will enroll 18 adults with advanced solid tumors that have spread or cannot be removed. The main goals are to find a safe dose and check for side effects, not yet to prove the drug works against cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AI-061 (a combination of two immunotherapy antibodies: anti-PD-1 and anti-CTLA-4)
What this could lead to
If this trial succeeds, it could point toward a new treatment option for several advanced solid tumors by boosting the immune system to fight cancer.
What could go wrong
This is a very early, small Phase 1 study with only 18 participants, focused on safety and dosing. It is not designed to prove the drug works, and side effects from immune activation can be serious.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cancer Research SA
Adelaide, South Australia, 5000, Australia
-
Mater Misericordiae Ltd.
Brisbane, Queensland, 4006, Australia
-
Southern Oncology Clinical Research Unit
Bedford Park, South Australia, 5042, Australia
-
St. Vincent's Private Hospital
Darlinghurst, New South Wales, 2010, Australia
-
Tasman Oncology Research
Southport, Queensland, 4120, Australia